-
Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology
As autumn arrives and the harvest season begins, China and France are joining hands to open a new chapter of collaboration. Hosted by the Chinese Medical Doctor Association and the Chinese Society for Immunology, and organized by the Hematology Physicians Branch of the Chinese Medical Doctor Association and the National Clinical Research Center for Hematologic…
-
Professor Bingcheng Liu: Exploring B-ALL from Personalized Immunity to Precision Immunotherapy | 2026 China-France Scientific Symposium on Hematology and Immunology
The 2026 China-France Scientific Symposium on Hematology and Immunology was held in Beijing from September 11 to 13, 2026. Building on the longstanding tradition of China-France exchanges in hematology, this year’s conference further expanded into the intersection of hematology and immunology, bringing together renowned experts in hematology and immunology from China and France to explore…
-
CSCO 2026 Global Perspective | Professor Franco Cavalli: From Teaching to Learning—Witnessing China’s Transformation in Oncology and Exploring Lymphoma Frontiers and ICML 2027 Highlights
The 29th Chinese Society of Clinical Oncology (CSCO) Annual Meeting was held in Jinan from September 16 to 19, 2026, bringing together leading oncology experts from around the world to explore pathways for innovation and advancement in precision cancer care. Professor Franco Cavalli, President of the International Conference on Malignant Lymphoma (ICML) and Professor at…
-
Professor Benkang Shi: Advancing Standardization and Precision—Challenges, Pathways, and Future Directions in Prostate Cancer Care in China | Pujiang Prostate Cancer Academic Conference
The Pujiang Prostate Cancer Academic Conference was recently held in Shanghai. Under the theme “Standardization, Precision, Chinese Innovation, and Global Collaboration,” the conference provided a high-level platform for academic exchange, focusing on key topics including early screening and precision diagnosis of prostate cancer, optimization of local treatment strategies, innovation in advanced disease management, and the…
-
2026 Pujiang Urologic Oncology Academic Conference | Professor Xiaojie Bian: ADCs Across the Entire Urothelial Carcinoma Treatment Continuum—Balancing Sequencing and Safety, From Earlier-Line Treatment to Cross-Payload Sequencing Strategies
The 2026 Pujiang Urologic Oncology Academic Conference was held in Shanghai. The rapid development of antibody–drug conjugates (ADCs) and immunotherapy is moving the treatment of urothelial carcinoma beyond later-line advanced disease to first-line treatment, the perioperative setting, and even non-muscle-invasive disease. At the same time, the clinical introduction of ADCs with multiple targets and payloads…
-
CACA GU | Professor Zhenghua Ju: Overcoming the Challenges of Precise Laparoscopic Suturing—From the Challenges of Vesicourethral Anastomosis and the 360° Suturing Theory to the Three Fundamental Principles of Surgical Suturing
Precise suturing is a key foundation for high-quality reconstruction in minimally invasive surgery. During laparoscopic radical prostatectomy, vesicourethral anastomosis tests the surgeon’s ability to control needle-holding angles and needle trajectories, while directly affecting procedural stability and reproducibility. In this interview, Oncology Frontier – UroStream invited Professor Zhenghua Ju of Fujian Cancer Hospital to discuss the…
-
Professor Hongkai Wang: Advancing Robotic Radical Prostatectomy Through Technical Innovation to Preserve Both Cancer Control and Function | Pujiang Prostate Cancer Academic Conference
The 2026 Pujiang Prostate Cancer Academic Conference was successfully held in Shanghai under the central theme of “Standardization, Precision Breakthroughs, Chinese Innovation, and Global Collaboration.” The conference aimed to promote the standardized diagnosis and treatment of prostate cancer in China while advancing key technological innovations. Following the meeting, Oncology Frontier – UroStream invited Professor Hongkai…
-
CACA GU | Professor Xiang Li: From Clinical Risk Stratification to Molecular Subtyping—A New Pathway to Precision Treatment for Advanced Renal Cell Carcinoma
Treatment decisions for advanced renal cell carcinoma (RCC) are shifting from traditional clinical risk stratification toward precision classification based on molecular characteristics. What is the scientific rationale behind this trend? Which key molecular biomarkers hold the greatest promise for guiding treatment selection and sequencing? And what are the major obstacles to translating scientific discoveries in…
Connecting Medical Expertise through Media